Awardee OrganizationUNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Description
Abstract Text
PROJECT SUMMARY/ABSTRACT
The overall goal of this Hyperpolarized MRI Technology Resource Center (HMTRC) renewal project is to
develop and disseminate optimal new hyperpolarized (HP) 13C MR technologies with requisite
training/documentation to advance significantly this emerging molecular imaging method driven push-pull by 13
Collaborative Projects (10 extramural). Through numerous preclinical and clinical research studies to date, it
has become clear both that HP 13C MR has outstanding research and clinical value, but also that virtually all
aspects of this technology (instrumentation, agent chemistry, DNP/dissolution methodology, MR acquisition,
and data analysis) require specialized developments to realize their full potential.
These new technologies, driven “push-pull” by the CPs, will be developed through three Technology Research
& Development (TRD) projects and provided to 12 Service Projects (10 extramural) to benefit their funded
research and disseminated widely to the general scientific community. TRD1 focuses on technology
development for polarizer and RF detector/exciter instrumentation. TRD2 will develop novel HP MR
molecular imaging probes tested in realistic preclinical models and correlative science studies. TRD3 will
develop new HP C-13 MR acquisition and free, open-source analysis software for the reconstruction, analysis,
and visualization of HP MR data specialized for CP and SP needs.
This proposed P41 renewal project was recently reviewed by our External Advisory Committee that is
comprised of experts in HP 13C MRI, clinical translation, and CP & SP PI’s. Their report states: “The EAC…is
unanimous in their assessment that the HMTRC is high functioning as an NCBIB. The HMTRC has led the
nation (and the world) in the development and translation of HP MRI through a unique combination of skills,
expertise, instrumentation, environment, clinical engagement, and industry engagement, which simply does not
exist elsewhere. The HMTRC will continue to serve as a critical national resource through the next funding
cycle as the field of HP MRI expands and matures, particularly with the clinical translation of new HP agents,
and more sites engaging in research involving human subjects. The restructured Center benefits from clear
and enhanced synergy between all TR&Ds and Collaborative Projects that are more broadly geographically
distributed. HMTRC programs for training and dissemination remain outstanding. Progress in the engagement
and stimulation of clinical interest is nothing short of remarkable, and crucial for the continuing growth and
development of this field.” The current P41 project was designed 5 years ago to focus on preclinical HP 13C
MR research, since at that time, human studies were only being conducted at UCSF. However, now that many
different sites are conducting clinical research studies with the support of this NCBIB, the new renewal P41 is
redesigned to facilitate widespread future clinical trials of HP 13C MRI to address unmet clinical needs.
Public Health Relevance Statement
PROJECT NARRATIVE
Hyperpolarized MR is an emerging molecular imaging method to monitor enzymatic conversions through key,
previously-inaccessible biochemical pathways. In this renewal project, this center aims to collaboratively
develop new technology with broad geographic and scientific diversity to advance this field in order to better
identify and understand human disease and to translate and disseminate these techniques for new clinical
trials and ultimately improved patient care.
NIH Spending Category
No NIH Spending Category available.
Project Terms
2,4-DinitrophenolAddressAdvisory CommitteesAlgorithmsBiochemical PathwayBioreactorsChemistryClinicalClinical ResearchClinical TrialsCommunicationCommunitiesComputer softwareDataData AnalysesDevelopmentDocumentationEducational workshopEnvironmentExtramural ActivitiesFundingFutureGeographyGoalsGrowth and Development functionHumanIndustryInfrastructureLeadershipMagnetic Resonance ImagingMethodologyMethodsMolecularMonitorMultimodal ImagingNewsletterPathologicPatient CarePhysician ExecutivesPhysiciansPre-Clinical ModelReportingResearchResearch PersonnelResolutionResourcesScienceScientistServicesSiteSoftware ToolsStructureTechniquesTechnologyTestingTimeTrainingTraining ProgramsTranslatingTranslationsValidationVisualizationVisualization softwareclinical translationdata infrastructuredata managementdesigndetectorhuman diseasehuman subjectimaging modalityimaging probeimaging studyimprovedinstrumentationinterestmetabolic imagingmolecular imagingnew technologynovelopen sourcepre-clinicalpre-clinical researchradiologistreconstructionresearch studyskillssocial mediasymposiumsynergismtechnology developmenttechnology research and developmentvirtualweb site
National Institute of Biomedical Imaging and Bioengineering
CFDA Code
286
DUNS Number
094878337
UEI
KMH5K9V7S518
Project Start Date
01-August-2011
Project End Date
28-February-2027
Budget Start Date
01-March-2024
Budget End Date
28-February-2025
Project Funding Information for 2024
Total Funding
$1,211,237
Direct Costs
$749,992
Indirect Costs
$461,245
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Biomedical Imaging and Bioengineering
$1,211,237
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5P41EB013598-13
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P41EB013598-13
Patents
No Patents information available for 5P41EB013598-13
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P41EB013598-13
Clinical Studies
No Clinical Studies information available for 5P41EB013598-13
News and More
Related News Releases
No news release information available for 5P41EB013598-13
History
No Historical information available for 5P41EB013598-13
Similar Projects
No Similar Projects information available for 5P41EB013598-13